Purple Biotech Ltd. (PPBT) Stock

Purple Biotech Ltd., a clinical-stage biopharmaceutical company based in Rehovot, Israel, is dedicated to advancing therapies aimed at overcoming tumor immune evasion and enhancing treatment options for cancer patients, particularly in the United States. The company's robust oncology pipeline includes CM24, a monoclonal antibody designed to block carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). CM24 is currently being evaluated in Phase 1b/2 clinical trials as part of combination therapy with anti-PD-1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer.

Additionally, Purple Biotech is developing NT219, a novel small molecule that targets insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT), pivotal proteins involved in cancer cell signaling pathways. NT219 is undergoing Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. These initiatives underscore the company's commitment to advancing innovative therapies that address critical unmet needs in oncology.

Founded as Kitov Pharma Ltd., Purple Biotech underwent a strategic transformation and rebranding in December 2020 to align its corporate identity with its focused mission in biotechnology and cancer treatment innovation. With a dedicated team of researchers and strategic partnerships driving its progress, Purple Biotech continues to forge ahead in its mission to bring novel cancer therapies to patients worldwide.